Proteins in blood associated with early lung cancer development found

Washington, Sept 13 (ANI): A team of scientists has discovered proteins in the blood that are associated with early lung cancer development in mice and humans.

The findings, by a team led by Samir Hanash, M.D., Ph.D., head of the Hutchinson Center's Molecular Diagnostics Program and member of its Public Health Sciences Division, brings the reality of a blood test for the early detection and diagnosis of lung cancer a step closer.

"A major feature of this study was that we were able to replicate findings from mouse models of lung cancer in blood samples from humans with lung cancer both at the time of diagnosis and, importantly, prior to the onset of symptoms and diagnosis," Hanash said.

"Our data showed that the protein markers that were tested showed similar concordance between lung cancer in the mouse and lung cancer in humans.

"This means that developing a blood test to detect lung cancer is increasingly within reach," he said.

The blood protein signatures discovered in the future may be used in a blood test to not only screen for lung cancer among high-risk individuals such as current and former smokers, but to aid in diagnosis, distinguishing between various subtypes of the disease, such as small-cell lung cancer and lung adenocarcinoma.

Hanash envisions that such a test could be used together with imaging technologies such as CT screening to monitor people at high risk of developing the disease.

For the study, the researchers conducted in-depth blood protein analysis of three mouse models of lung adenocarcinoma and a genetically engineered mouse model of small-cell lung cancer.

In models of lung adenocarcinoma, the researchers uncovered a set of elevated proteins that are regulated by the NKX2.1 transcription factor, which has been linked to lung development and function.

They also discovered a network of dysregulated proteins linked to epidermal growth factor receptor which, when mutated in lung tissue, is associated with cancer development. Levels of these proteins returned to near normal upon treatment with a tyrosine kinase inhibitor, an anti-cancer drug.

In a model of small-cell lung cancer, the researchers found a distinct blood protein signature that was associated with neuroendocrine development.

The researchers found striking similarities between the protein signatures in mice and human. For example, in mice with small-cell lung cancer, they found elevated levels of a neural protein called Robo1.

They also found significantly increased levels of this protein in patients with small-cell lung cancer as compared to matched human controls.

The findings have been published online September 12 ahead of the September 13 print issue of Cancer Cell. (ANI)